Erik Mogalian

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

John O. Link, James G. Taylor, Lianhong Xu et al. · Journal of Medicinal Chemistry · 2013 · 290 citations

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

David Wyles, Norbert Bräu, Shyam Kottilil et al. · Clinical Infectious Diseases · 2017 · 156 citations · Full text

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection

Stephen Pianko, Steven L. Flamm, Mitchell L. Shiffman et al. · Annals of Internal Medicine · 2015 · 94 citations · Full text

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Erik Mogalian, Polina German, Brian P. Kearney et al. · Clinical Pharmacokinetics · 2015 · 52 citations

Multiple Probes, Medicine, Antiviral Drug Development +6

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · 2021 · 52 citations · Full text

Adverse Events, Covid-19 Pandemic, Clinical Epidemiology +14